Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

284P - Interest of a multidisciplinary approach in the initiation of oral therapies in metastatic breast cancer (MBC): Experience of a French comprehensive cancer center

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Breast Cancer

Presenters

Charlotte Dupont

Citation

Annals of Oncology (2020) 31 (suppl_4): S348-S395. 10.1016/annonc/annonc268

Authors

C. Dupont1, A. Morel1, B. Martel2, C. Duval1, F. Divanon2, C. Levy1

Author affiliations

  • 1 Department Of Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 2 Department Of Pharmacy, Centre Francois Baclesse, 14076 - Caen/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 284P

Background

The growing number of oral therapies indicated for MBC highlights the need of a specific approach in order to improve both compliance and safety of these new drugs. This observation led the François Baclesse Cancer Center to initiate a pathway for initial prescription (chemotherapies and targeted therapies), thanks to a multidisciplinary team with a specific role for each professional. We present here the results of a prospective observational study of the first year of this pathway.

Methods

After indication of an oral therapy for MBC, each patient benefits of 3 consultations (medical oncologist, pharmacist, breast care nurse). During the medical visit, the oncologist is in charge of the treatment prescription and patient’s information about the risk of adverse events (AEs). The role of the pharmacist is both before the medical visit (informs the medical oncologist on possible drug-drug interactions) and after (informs the patient about the personalized treatment calendar, detects potential interactions with herbal medicine or food). The breast care nurse ensures a comprehensive education aiming to help patients to anticipate side effects (for example, what type of AEs can be managed at home and how), and evaluates the need of supportive care. A data collection was conducted during 14 months, from December 2018 to February 2020.

Results

270 patients benefited from this multidisciplinary consultation between December 2018 and February 2020, 193 targeted therapies and 77 chemotherapies were prescribed. In total, 36% of pharmaceutical interventions (PI) were carried out. 46% of PI led to a discontinuation of one of the drugs usually taken by the patient, 19% led to a substitution, 13% to a dosage adjustment. The whole results will be presented at the congress.

Conclusions

The aim of this multidisciplinary consultation is to provide a safe medication management and preserve quality of life of patients. This will help maintaining patient autonomy, increasing adherence and patient satisfaction. Finally, this approach aim to reinforce the link between hospital and ambulatory care by encouraging relations between professionals.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.